Jiangzhong pharmaceutical: it is estimated that the total operating revenue in the first quarter of 2022 will be about 890 million yuan, with a year-on-year increase of about 30%

IntoCare Zhang Hui: Ingenuity Forges Quality, Continuous Improvement Safeguards Lives

In 2024, nearly all medical enterprises are exploring overseas markets. This trend is driven by an anti-corruption wave within the medical industry, the demand for financing and initial public offerings, as well as challenges such as excess production capacity. Presently, venturing abroad has become an essential developmental path for medical device enterprises. Successfully entering foreign markets is not only a crucial means for the medical industry to achieve a second grow

250 Million Dollars, Mousse Shares Acquisition of Singapore “Counterparts”

On the evening of December 17, Mousse shares released an announcement that it intends to acquire, through its subsidiaries, 100% of the equity of the Singaporean company MIPL (Mattress International Pte. Ltd.), as well as all the assets of its Indonesian factory PTTC.

Vietnam Assists Laos in Advancing Population Management and Identification System

Cambodia Issues New Regulations to Govern Crypto Asset Transactions by Financial Instituti

CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM

There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?